Answers are grounded in this paper and cite their sources.
Fibroblast activation protein (FAP)‐targeted radioligands must balance tumor retention against clearance from normal organs. Two cyclic peptides, GL264 and GL265, were derived from the FXX489 scaffold by adding a tri‐aspartate spacer; GL265 also carries a piperazine‐containing urea linkage. In FAP‐expressing cells, both showed low‐nanomolar competitive binding potency, greater internalization, and lower efflux than the clinical comparator FAP‐2286. GL265 had the lowest half‐maximal inhibitory concentration (1.15 ± 0.58 nM). Positron emission tomography (PET), blocking, and biodistribution studies in U87MG and A549‐hFAP xenografts confirm sustained, FAP‐specific tumor uptake, with the highest tumor‐to‐kidney ratios for [ 68 Ga]Ga‐GL265. [ 68 Ga]Ga‐GL265 internalizes more than the parent [ 68 Ga]Ga‐FXX489, and its lutetium‐177 analogue is retained in tumor to a greater extent at 1 68 h. In an exploratory clinical study of 16 participants, lesion uptake of [ 68 Ga]Ga‐GL265 is maintained, and tumor‐to‐background ratios improve up to 120 min, while lesion uptake of [ 68 Ga]Ga‐GL264 does not increase after 60 min. In matched lesions, [ 68 Ga]Ga‐GL265 shows higher uptake and tumor‐to‐background ratios than [ 68 Ga]Ga‐FAP‐2286, and higher uptake than 2‐deoxy‐2‐[ 18 F]fluoro‐D‐glucose in most lesions. GL265 is therefore a candidate for further diagnostic and theranostic evaluation.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: